Argenica Therapeutics Ltd - Asset Resilience Ratio

Latest as of June 2023: 0.52%

Argenica Therapeutics Ltd (AGN) has an Asset Resilience Ratio of 0.52% as of June 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

AU$50.00K

≈ $35.38K USD Cash + Short-term Investments

Total Assets

AU$9.54 Million

≈ $6.75 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2022–2022)

This chart shows how Argenica Therapeutics Ltd's Asset Resilience Ratio has changed over time. See Argenica Therapeutics Ltd leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.

Liquid Assets Composition Over Time

This chart breaks down Argenica Therapeutics Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Argenica Therapeutics Ltd stock valuation.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	AU$0.00	0%
Short-term Investments	AU$50.00K	0.52%
Total Liquid Assets	AU$50.00K	0.52%

Asset Resilience Insights

Limited Liquidity: Argenica Therapeutics Ltd maintains only 0.52% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Argenica Therapeutics Ltd Industry Peers by Asset Resilience Ratio

Compare Argenica Therapeutics Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
argenx NV ADR NASDAQ:ARGX	Biotechnology	10.93%
Shanghai Allist Pharmaceuticals Co. Ltd. A SHG:688578	Biotechnology	21.11%
Tubize-Fin BR:TUB	Biotechnology	0.05%
Tango Therapeutics Inc NASDAQ:TNGX	Biotechnology	57.90%
TELIX Pharmaceuticals Ltd AU:TLX	Biotechnology	32.29%
Inner Mongolia Furui Med Sci SHE:300049	Biotechnology	2.34%
Bicara Therapeutics Inc. Common Stock NASDAQ:BCAX	Biotechnology	39.07%
Damora Therapeutics, Inc. NASDAQ:DMRA	Biotechnology	0.00%

Annual Asset Resilience Ratio for Argenica Therapeutics Ltd (2022–2022)

The table below shows the annual Asset Resilience Ratio data for Argenica Therapeutics Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2022-12-31	0.52%	AU$50.00K ≈ $35.38K	AU$9.54 Million ≈ $6.75 Million	--

pp = percentage points

About Argenica Therapeutics Ltd

AU:AGN Australia Biotechnology

Market Cap

$13.63 Million

AU$19.27 Million AUD

Market Cap Rank

#26235 Global

#1188 in Australia

Share Price

AU$0.15

Change (1 day)

-3.23%

52-Week Range

AU$0.09 - AU$0.73

All Time High

AU$0.99